



INTELLECTUAL  
PROPERTY OFFICE  
BRUNEI DARUSSALAM

**30 November 2023**

**NO. 011/2023**



# PATENT JOURNAL

**Brunei Darussalam Intellectual Property Office (BruIPO)**

The Law Building, Ground Floor

Jalan Raja Isteri Pengiran Anak Saleha

Bandar Seri Begawan BA1910

Negara Brunei Darussalam

Tel: +673 2244873/4/5/6 Ext 102

Email: [enquiries@bruipo.gov.bn](mailto:enquiries@bruipo.gov.bn)

Brunei Darussalam Intellectual Property Office (BruIPO) © 2013. All rights reserved. Modification or reproduction of this Journal without the permission of BruIPO is prohibited.





## CONTENTS

General Information	3
Operating Hours	3
Submission of Application	3
Enquiries	3
Patents Legislation	4
Forms and Fees	4
INID Codes	5
First Schedule – Fees	7
Second Schedule – Forms	15
Third Schedule – Scale of Cost Part 1 – Basic Costs	19
Part II – Additional Cost	20
Fourth Schedule – Micro-Organisms	21
Fifth Schedule – Remuneration of Scientific Advisers	27
New Patent Applications Filed	34
Patent Renewal Application	54
Patent Granted	79
Patent Recordal of Change of Name & Address	80
Patent Recordal of Change of Agent	82

\*\*\*\*\*

### **General Information**

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)  
Attorney General's Chamber  
The Law Building,  
Jalan Raja Isteri Pengiran Anak Hajah Saleha,  
Bandar Seri Begawan BA1910  
Brunei Darussalam  
Tel: +673 2225919

### **Opening Hours**

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	: 8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	: 8.00am to 11.00am
Friday and Sunday	: CLOSED

### **Submission of Applications**

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).
2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

### **Enquiries**

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B\$10.00 per copy.
2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is <http://www.bruipo.gov.bn>.
3. All Patent-related enquiries via email can be submitted to [enquiries@bruipo.gov.bn](mailto:enquiries@bruipo.gov.bn)

\*\*\*\*\*

### **Patents Legislation**

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.
2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541
3. The soft copies of the legislation can be obtained from [www.bruipo.gov.bn](http://www.bruipo.gov.bn)

### **Forms and Fees**

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.
2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

### **Restrictions on Applications Abroad by Residents of Brunei Darussalam**

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.
2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

### **Transitional Applications**

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:
  - Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
  - Lodgement of Patent Form PF46;
  - Certified true copy of the grant of patent in the relevant country;
  - Prescribed fee of B\$250.00; and
  - Any other supporting documents that the Registrar deems necessary.
2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.



3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of \$6.50 per hour.

\*\*\*\*\*



## **'INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS**

'INID' is an acronym for **I**nternationally agreed **N**umbers for the **I**dentification of **D**ata'

(10) Document identification

- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data

- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information

- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document



- (70) Name(s) of nominated person
- (71) Name(s) of applicant(s).
- (72) Name(s) of inventor(s) if known to be such.
- (74) Name(s) of attorney(s) or agent(s).
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

- (80) Identification of data related to International Conventions other than the Paris Convention
  - (86) PCT Application Number.
  - (87) PCT Publication Number.

**NOTE**

- (1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
- (2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.

\*\*\*\*\*

## **PRACTICE NOTE 2012/01**

### **PATENT RENEWALS**

- **RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER**

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

- (a) PF20;
- (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
- (c) evidence of the original patent not having been revoked, and
- (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

2. **PF20**

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

3. **PF46**

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

4. **PF21**

Extension fees will become payable for renewals as of 1 January 2013.

5. **Certification of original patent**

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a



statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

**AMENDMENT OF RULE 92 OF S 19/2012**

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

“(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.”.

**AMENDMENTS AND CORRECTIONS**


- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**

1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.
2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.


- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**

1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.
2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.

**Example 1: Page 10 of 19 sheets (Specification) is amended**




**Example 2: Page 10 of 19 sheets (Specification) is amended**






**Example 3: Page 10 of 19 sheets (Specification) is amended**



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

**Example 4: Page 10 of 19 sheets (Specification) is amended**



- **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

### **REGISTRATION UNDER SECTION 115**

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

---

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA

\*\*\*\*\*

## **FIRST SCHEDULE**

### **FEES PAYABLE**

<b><u>Matter</u></b>	<b><u>Fee</u></b>	<b><u>Corresponding Form(s)</u></b>
1. On filing a request for the grant of a patent	\$160.00	1
2. On reference under section 20(1) or 48(1)	\$450.00	2
3. On filing a counter-statement in each of the following cases –	\$40.00	3
(a) Opposing the making of an order under section 20 or 48		
(b) Opposing a request under section 22		
(c) In respect of a reference under section 23(5)		
(d) Opposing an application under section 24		
(e) In answer to a notice of opposition under section 38		
(f) In answer to a notice of opposition under section 41		
(g) In respect of a reference under section 49(5)		
(h) In respect of an application under section 55(3)		
(i) In answer to a notice of opposition under section 56(7)		
(j) In respect of a reference under section 65(3)		
(k) On contesting an application under section 76 for declaration of non- infringement		
(l) On contesting an application under section 77 for revocation of a patent		
(m) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	\$50.00	4
5. On request for directions under section 22	\$450.00	5



6. On reference under section 23(5) or 49(5) to determine the question of licence	\$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	\$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	\$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	\$1750.00	11
12. On filing a request for a search and examination report	\$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	\$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(a) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00	
(b) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00 plus \$20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20



(a) for each year in respect of the 5th, 6th or 7th year of the patent		
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$160.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$270.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$350.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$450.00	
(f) for the 20th year of the patent	\$550.00	
(g) for each year after the 20th year of the patent	\$650.00	
	\$950.00	
20. On payment of an additional fee for renewal under 21 section 35(3) –		21
(a) not exceeding one month	\$50.00	
(b) each succeeding month (but not exceeding 6 months)	\$100.00	
21. On application to amend specification after grant	\$100.00	22
22. On notice of opposition to amendment of specification after grant	\$480.00	23
23. On application for the restoration of a patent	\$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	\$300.00	25
25. On filing an offer to surrender a patent	\$70.00	26
26. On notice of opposition to offer to surrender a patent	\$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	\$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –		
	\$12.00	28
(a) each alteration or correction of name		



(b) each alteration or correction of address (not being an address for service)

29. On filing a request, in respect of each patent or application for a patent, for – \$12.00 28

(a) each alteration or correction of address for service

(b) each correction of an error in the register or any connected document

(c) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application

30. On request for the furnishing of or access to miscellaneous information – 30

(a) fee for inspecting each file or document relating to a patent or patent application \$6.50

(b) fee for furnishing each file or document \$6.00

(c) fee for photocopying each page or part thereof of any other document by the staff of the Registry \$0.30

(d) where the document is placed in the public search room –

(i) fee for self-service photocopying of each page or part of the document using a stored-value card \$0.15

(ii) fee for photocopying of each page or part thereof by the staff of the Registry \$0.30

31. On request for certificate of the Registrar – 31

(a) by impressed stamp -

(i) for the first 20 sheets \$18.00

(ii) for each additional sheet thereafter \$0.30

(b) sealed and attached to the documents -

(i) for the first 20 sheets \$30.00





(ii) for each additional sheet thereafter	\$0.30	
(c) in respect of a priority document under rule 17.1(b) of the Regulations under the Patent Cooperation Treaty	\$50.00	
(d) in respect of a certified copy of the international application for a patent under rule 124	\$28.00	
32. On application for entry of order of court in the register	\$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	\$70.00	33
34. On application for settlement of terms of licence of right	\$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	\$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	\$90.00	36
37. On reference to the Registrar of a dispute as to infringement	\$280.00	37
38. On application for declaration of non- infringement	\$280.00	38
39. On application under section 77 for the revocation of a patent	\$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	\$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	\$160.00	42
42. On payment of prescribed fee and request for publication of translation	\$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	\$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	\$100.00	48



45. On declaration of authorisation where agent appointed or in substitution for another	\$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	\$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	\$100.00	48
48. On request for information relating to a patent or an application for a patent	\$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	\$200.00	50
50. On request for extension of each time or period under rule 114(6)	\$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	\$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(a) –		51
(a) where the application is not an international application for a patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	\$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	\$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(a) of the Regulations under the Patent Co-operation Treaty	\$250.00	-



55. On request for certificate authorising release of sample of micro-organism	\$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	\$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	\$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	\$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$275.00	
(f) for the 20th year of the patent	\$325.00	
(g) for each year after the 20th year of the patent	\$475.00	
59. On application to extend the term of a patent under section 36	\$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	\$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	\$3100.00	
(c) where the Examiner is the Hungarian Patent Office	\$2680.00	
61. On filing one or more documents under section 26(7)(c) or (8) or 28(8)	-	61



62. On filing a declaration under rule 9(2) or a request under rule 9(3)	\$120.00	62
63. On filing a request under rule 10(2)	\$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	\$2.00	
(b) for each sheet of information printed	\$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	\$10.00	
(b) Patents Journal B	\$36.00	

\*\*\*\*\*



## **SECOND SCHEDULE**

### **DESCRIPTIONS OF FORMS**

<b><u>No.</u></b>	<b><u>Description of Form</u></b>	<b><u>Corresponding Form No.</u></b>
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(e)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17



20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 41(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36



39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(a)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53



56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(d)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(c) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99

\*\*\*\*\*





### **THIRD SCHEDULE**

#### **SCALE OF COSTS**

##### **PART I**

##### **BASIC COST**

<i>Item</i>	<i>Matter</i>	<i>Amount</i>
1	Drawing and filing notice of opposition or application for revocation together with statement of case	\$200.00
2	Drawing and filing a counter-statement	\$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	\$200.00 - \$800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	\$2.00 per folio
5	Preparing for all interlocutory proceedings	\$25.00 - \$120.00
6	Attending all interlocutory proceedings	\$25.00 - \$50.00
7	Preparing for hearing	\$500.00 - \$1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	\$100.00 per hour up to a maximum of \$450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	\$60.00 per hour up to a maximum of \$270.00 per day
10	Advocate or Solicitor fees	\$120.00 per hour up to a maximum of \$540.00 per day
11	Drawing bill of costs (per folio)	\$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	\$50.00 - \$120.00

\*\*\*\*\*



## **PART II**

### **ADDITIONAL COSTS**

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.
2. A person attending proceedings before the Registrar shall be paid –
  - (a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and
  - (b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of \$250 for meals and accommodation.
3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –
  - (a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed \$150 per day; or
  - (b) in any other case, an amount of not less than \$100 but not more than \$150 for each day on which he so attends.

\*\*\*\*\*

## **FOURTH SCHEDULE**

### **MICRO-ORGANISMS**

#### **Applications.**

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

- (a) which is not available to the public at the date of filing of the application; and
- (b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

- (2) The conditions referred to in sub-paragraph (1) are –

- (a) a condition that –

- (i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and
  - (ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and
- (b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

- (3) Where the condition of sub-paragraph (2)(a)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

- (a) within 16 months from –

- (i) the declared priority date; or
- (ii) the date of filing the application where there is no declared priority date;

- (b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the

date of the request; or

- (c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.

(4) The giving of the information specified in sub-paragraph (2)(a)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

### **Availability of cultures.**

2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –

- (a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(c); and

- (b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.

- (2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –

- (a) to the applicant for, or proprietor of, the patent;

- (b) to the international depositary authority; and (c) to the person making the request.

- (3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –

- (a) not to make the culture, or any culture derived from it, available to any other person; and

- (b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –

- (i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,

where an application is reinstated under either of those rules, the period before it is reinstated);

- (ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and
- (iii) the undertaking set out in sub-paragraph (b) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

(a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and

(b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(a) has effect –

(a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or

(b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

### **Availability of cultures to experts.**

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

(a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and

(b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is

treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(a) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(a) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;

(b) to the international depositary authority concerned;

(c) to the requester; and

(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons

referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(a) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

### **New deposits.**

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and



- (c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

- (a) shall, subject to sub-paragraph (b), be made with the same international depositary authority as was the original deposit; or
- (b) in the cases referred to in sub-paragraphs (1)(a)(ii), (b) and (c), shall be made with another international depositary authority which is able to satisfy the request.

### **Interpretation.**

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

- (a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and
- (b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.



## **FIFTH SCHEDULE**


### **REMUNERATION OF SCIENTIFIC ADVISERS**

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –
  - (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and
  - (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of \$250.
2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than \$650 but not more than \$2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(b).
3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than \$650 but not more than \$2,000 if he is subsequently not required to hear the proceedings with the Registrar.

\*\*\*\*\*

# NEW PATENT APPLICATION

[Fig 2]



- 
- [21] BN/N/2023/0105 [22] 25/09/2023
- [54] Anti-Cd122 Antibodies And Uses Thereof
- [71] VILLARIS THERAPEUTICS, INC. of 2500 Regency Parkway Cary, North Carolina 27518, United States of America
- [72] 1. FINLAY, WILLIAM JAMES JONATHAN  
2. HARRIS, JOHN E.  
3. LUONGO, MATTHIEU
- [74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.
- [31][32][33]  
No. 63/174,772 Date: 14/04/2021 Country: United States of America  
No. 63/279,762 Date: 16/11/2021 Country: United States of America
- [86] PCT/US2022/024620
- [87] WO/2022/221409
- [51] C07K 16/28, C12N 15/13, A61K 39/395, A61K 47/68, A61P 37/02
- [57] Provided herein are antibody molecules that bind specifically to CD122 and antigen-binding portions thereof and related compositions, nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.




FIG. 1

- [21] BN/N/2023/0106 [22] 26/09/2023
- [54] Anti-Nectin-4-Antibodies And Uses Thereof
- [71] EMERGENCE THERAPEUTICS AG of Schifferstrasse 210, 47059 Duisburg, Germany  
UNIVERSITE D'AIX-MARSEILLE of 58 Boulevard Charles Livon, 13007 Marseille, France  
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) of 101 rue de Tolbiac, 75013 Paris, France  
INSTITUT JEAN PAOLI & IRENE CALMETTES of 232 Boulevard SainteMarguerite, 13009 Marseille, France  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS of 3, rue Michel Ange, 75016 Paris, France
- [72] 1. ELANDS, Jack  
2. PRÉVILLE, Xavier  
3. OLIVE, Daniel  
4. LOPEZ, Marc
- [74] Messrs. MIRANDAH ASIA (SINGAPORE) PTE. LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 21166441.2 Date: 31/03/2021 Country: European Patent Office  
No. 21170941.5 Date: 28/04/2021 Country: European Patent Office  
No. 21172723.5 Date: 07/05/2021 Country: European Patent Office  
No. 21209332.2 Date: 19/11/2021 Country: European Patent Office

- [86] PCT/EP2022/058626
- [87] WO/2022/207822
- [51] C07K 16/28, A61K 38/00, A61K 38/17, A61K 41/00, A61K 47/50, A61K 47/68, A61K 49/00, A61P 35/00
- [57] The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
- 

- [21] BNN/2023/0107 [22] 26/09/2023
- [54] Anti-Nectin-4-Antibodies Exatecan Conjugates
- [71] EMERGENCE THERAPEUTICS AG of Schifferstrasse 210, 47059 Duisburg, Germany  
UNIVERSITE D'AIX-MARSEILLE of 58 Boulevard Charles Livon, 13007 Marseille, France  
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) of 101 rue de Tolbiac, 75013 Paris, France  
INSTITUT JEAN PAOLI & IRENE CALMETTES of 232 Boulevard SainteMarguerite, 13009 Marseille, France  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS of 3, rue Michel Ange, 75016 Paris, France
- [72] 1. ELANDS, JACK  
2. LHOSPICE, FLORENCE  
3. PRÉVILLE, XAVIER  
4. OLIVE, DANIEL  
5. LOPEZ, MARC
- [74] Messrs. MIRANDAH ASIA (SINGAPORE) PTE. LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 21166441.2 Date: 31/03/2021 Country: European Patent Office  
No. 21170941.5 Date: 28/04/2021 Country: European Patent Office  
No. 21172723.5 Date: 07/05/2021 Country: European Patent Office  
No. 21209332.2 Date: 19/11/2021 Country: European Patent Office

- [86] PCT/EP2022/058629
- [87] WO/2022/207825

[51] C07K 16/28, A61K 47/68, A61P 35/00

[57] The present invention relates to an antibodies-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drugs is a topoisomerase I inhibitor, particularly exatecan.

---

[21] BN/N/2023/0108

[22] 02/10/2023

[54] MULTISPECIFIC BINDING MOIETIES COMPRISING NOVEL PD-1 BINDING DOMAINS

[71] MERUS N.V. of Uppsalalaan 17, 3rd & 4th Floor 3584 CT Utrecht, Netherlands  
INCYTE CORPORATION of 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States of America

[72] 1. PLYTE, SIMON EDWARD  
2. MAYES, PATRICK  
3. NASTRI, HORACIO G.  
4. STEWART, SHAUN M.

[74] Messrs. GATEWAY LAW CORPORATION of AIP LAW, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 2027893 Date: 21/03/2021 Country: Netherlands

[86] PCT/US2022/022564

[87] WO/2022/212516

[51] C07K 16/28, A61P 35/00

[57] The present disclosure relates to multispecific binding moieties comprising novel PD- 1 binding domains that have a higher binding affinity for human PD-1 than a reference PD-1 binding domain. Such multispecific binding moieties further provide a comparable, or equal or higher, potency in blocking ligand binding to human PD-1 than a reference PD-1 antibody. The present disclosure in particular relates to multispecific binding moieties comprising a novel PD-1 binding domain and a LAG-3 binding domain. Also provided is a method for treating a disease, in particular a disease associated with a suppressed immune system, such as cancer, with a multispecific binding moiety of the present disclosure. The present disclosure further relates to a vector and cell comprising nucleic acids encoding a novel PD-1 binding domain and a LAG-3 binding domain.

---



- [21] BN/N/2023/0109 [22] 02/10/2023
- [54] **POLYETHYLENE-BASED RESIN COMPOSITION AND POLYETHYLENE-BASED RESIN PACKAGING MATERIAL**
- [71] **SANIPAK COMPANY OF JAPAN, LTD. of 1-25-5, Hitagaya, Shibuya-ku, Tokyo 1510072, Japan**
- [72] **1. HORIGOME YOSHIHIRO  
2. OSAKI MANABU  
3. NAKAGAWA YASUHIRO**
- [74] **Messrs. CCW PARTNERSHIP of Unit 9 & 10, 2nd floor, Block C, Kiarong Complex, Lebuhraya Sultan Hassanah Bolkiah Bandar Seri Begawan BE1318, Brunei Darussalam, Bandar Seri Begawan 8674**
- [31][32][33]
- [86] **PCT/JP2021/015975**
- [87] **WO/2022/224333**
- [51] **C08L 23/00**
- [57] **An object of the present invention is to provide: a polyethylene-based resin composition from which a film with favorable film strength, elongation, sealing strength, and impact strength can be produced even where an inorganic compound added; and a polyethylene-based resin packaging material. This polyethylene-based resin composition contains an inorganic compound and a resin component, in which the resin component includes an ethylene- $\alpha$ -olefin copolymer A which is obtained by copolymerization ethylene and an  $\alpha$ -olefin having 6 to 8 carbon atoms, in which a melt flow rate is 0.8 g/10 min or more and 4.0 g/10 min or less; and includes either or both of high-density polyethylene and an ethylene- $\alpha$ -olefin copolymer B which is obtained by copolymerization ethylene and an  $\alpha$ -olefin having 4 carbon atoms, a content of the inorganic compound is 30% by mass or more and 65% by mass or less with respect to a total mass of the resin composition, and a content of the ethylene- $\alpha$ -olefin copolymer A is 50% by mass or more and 95% by mass or less with respect to a total mass of the resin component.**

- 
- [21] BN/N/2023/0110 [22] 03/10/2023
- [54] **Agonistic Anti-II-2r Antibodies And Methods Of Use**
- [71] **TENEOBIO, INC. of One Amgen Center Drive Thousand Oaks, California 91320,**

**United States of America**

- [72]      1. TRINKLEIN, NATHAN  
            2. HARRIS, KATHERINE  
            3. LORENTSEN, KYLE  
            4. MALIK CHAUDHRY, HARBANI KAUR  
            5. LOUGHLIN, KAITLYN
- [74]      Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 63/170,383 Date: 02/04/2021 Country: United States of America  
No. 63/239,883 Date: 01/09/2021 Country: United States of America

- [86]      PCT/US2022/023058
- [87]      WO/2022/212848
- [51]      C07K 16/28, A61K 39/395, A61P 37/04

- [57]      Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.

**FIG. 1**

Name	Kinetics			
	IL2RB KD (M)		IL2RG KD (M)	
	Human	Cyno	Human	Cyno
IL2RB_F09C**IL2RG_F16A	1.85E-08	1.07E-08	1.79E-09	4.87E-09
IL2RB_F09G**IL2RG_F16B	9.34E-08	1.67E-08	1.71E-08	5.02E-08
IL2RB_F09G**IL2RG_F16C	9.67E-08	1.60E-08	1.43E-09	3.58E-09
IL2RB_F09G**IL2RG_F16A	8.24E-08	1.73E-08	2.93E-09	5.81E-09
IL2RB_F09K**IL2RG_F16B	1.82E-07	1.65E-08	2.01E-08	4.15E-08
IL2RB_F18E**IL2RG_F16A	5.38E-08	5.52E-08	1.88E-09	5.42E-09

[21]      BN/N/2023/0111      [22]      07/10/2023

- [54]      Methods For Treating Cancer With Subcutaneous Administration Of Anti-Pd1 Antibodies



[71] **MERCK SHARP & DOHME LLC of 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America**

[72] **1. LALA, MALLIKA  
2. DE MIRANDA SILVA, CAROLINA  
3. KRISHNAMACHARI, YOGITA  
4. CHARTASH, ELLIOT KEITH  
5. JAIN, LOKESH  
6. VADDADY, VENKATA NAGA RATNA PAVAN KUMAR**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
No. 63/172,299 Date: 08/04/2021 Country: United States of America

[86] **PCT/US2022/023250**

[87] **WO/2022/216580**

[51] **C07K 16/30**

[57] **The invention relates to methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody, or antigen binding fragment thereof, (e.g. pembrolizumab), in specific amounts to the patient. In some embodiments, the administration occurs about every three weeks. In some embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 280 mg to about 450 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.**




FIG.2

[21] BN/N/2023/0112 [22] 07/10/2023

[54] STEEL PIPE FOR OIL-WELL

[71] NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 100-8071, Japan  
VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOVE-AYMERIES, 59620 France

[72] 1. OSHIMA, MASAHIRO

[74] Messrs. CCW PARTNERSHIP of Unit 9 & 10, 2nd floor, Block C, Kiarong Complex, Lebuhraya Sultan Hassanah Bolkiah, Bandar Seri Begawan BE1318, Brunei Darussalam, Bandar Seri Begawan 8674

[31][32][33]


No. 2021-075844 Date: 28/04/2021 Country: Japan

[86] PCT/JP2022/016384

[87] WO/2022/230595

[51] F16L 15/04, E21B 17/00, E21B 17/042


[57] An oil-well steel pipe including a Zn-Ni alloy plating layer has excellent galling resistance is provided. An oil-well steel pipe according to the present disclosure includes: a pipe main body that includes a pin which includes a pin contact surface, and a box which includes a box contact surface; and a Zn-Ni alloy plating layer which is formed on at least one of the pin contact surface and the box contact surface. The chemical composition of the pipe body contains, in mass%, C: 0.01 to 0.60%, Cr: 0 to 8.0%, and Fe: 80.0% or more. In addition, when a region containing C in an amount that, in mass% is 1.5 times or more greater than the C content of the pipe main body is defined as a C-concentrated layer, the thickness of the C-concentrated layer in the wall thickness direction of the pipe main body is within the range of 0 to 1.50  $\mu\text{m}$ .



**[22] 07/10/2023**

[57] This invention provides an oil well steel pipe with a threaded connectin with which excellent galling resistance is obtained without using a compound grease, and which can suppress the occurrence of rust on a pin contact surface and can also keep shouldering torque at a low level. An oil well steel pipe with a threaded connection of the present disclosure includes a pipe main body 10 including a first end portion 10A and a second end section 10B. The pipe main body 10 includes a pin 40 formed at the first end portion 10A, and a box 50 formed at the second end portion 10B. A light oil 80 is applied to a pin contact surface 400 of the pin 40. A solid lubricant coating 60 is formed on a box contact surface 500 of the box 50.

FIG. 11



[21]	BN/N/2023/0114	[22]	07/10/2023
[54]	Anti-Tslp Antibody Compositions And Uses Thereof		
[71]	AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America		
[72]	1. ZHANG, HAO 2. POLOZOVA, ALLA 3. FITZPATRICK, KELLY 4. ABRAMS, KRISTIN 5. XIANG, DONG 6. JOUBERT, MARISA		
[74]	Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.		
[31][32][33]	No. 63/178,938 Date: 23/04/2021 Country: United States of America		
[86]	PCT/US2022/025994		
[87]	WO/2022/226339		
[51]	C07K 16/06, C07K 16/24		
[57]	The present application relates, in general, to compositions comprising anti-TSLP antibody tezepelumab and derivatives thereof having antibody quality attributes.		

[21]	BN/N/2023/0115	[22]	16/10/2023
------	----------------	------	------------

- [54] **Composition, Kit, And Application For Detection Of Colorectal Cancer**
- [71] **BGI GENOMICS CO., LTD. of Floors 7-14, Building No.7, BGI Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong 518083 China**
- [72] **1. WANG, YUYING  
2. PENG, JIAXI  
3. SUN, JIANLONG  
4. JIANG, RUIJINGFANG  
5. ZHENG, JIANCHAO  
6. ZHU, SHIDA**
- [74] **Messrs. HENRY GOH & CO. SDN. BHD. of AIP LAW, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemanha, Bandar Seri Begawan BS8811, Brunei Darussalam.**
- [86] **PCT/CN2021/089368**
- [87] **WO/2022/222146**
- [51] **C12N 15/11**
- [57] **Provided are a composition, a kit, and an application for the detection of colorectal cancer. The provided composition contains a reagent used for detecting methylation state of the ADHFE1 gene, PPP2R5C gene, and SDC2 gene, The composition can be used for the detection colorectal cancer with high sensitivity and specificity.**

---

[21] **BN/N/2023/0116** [22] **30/10/2023**

- [54] **Use Of Medicament In Treatment Of Tumor Disease**
- [71] **SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. of No.666, Xinhua Avenue (Section 2) Hai Xia Industrial Park, Wenjiang District Chengdu, Sichuan 611138, China**
- [72] **1. GE, JUNYOU  
2. OUYANG, XUENONG  
3. JIN, XIAOPING  
4. DIAO, YINA  
5. LIU, GESHA  
6. CHENG, YEZHE  
7. WANG, JINGYI  
8. XU, YING  
9. RAO, CHUN**

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 202110482012.2 Date: 30/04/2021 Country: China

[86] PCT/CN2022/089737

[87] WO/2022/228497

[51] A61K 39/395, A61K 45/06, A61P 35/00

[57] The present invention relates to the use of a medicament in treatment of a tumor disease. In particular, the present invention provides the use of a biologically active conjugate represented by formula (I) in treatment of a tumor disease. The tumor disease particularly and preferably refers to an unresectable locally advanced or metastatic solid tumor that is refractory according to existing treatment standards, including but not limited to breast cancer, gastric cancer, lung cancer, ovarian cancer, urinary tract epithelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer, and brain tumor.




图 1

[21] BN/N/2023/0117

[22] 04/11/2023

[54] Compounds And Uses Thereof

[71] FOGHORN THERAPEUTICS INC. of 500 Technology Square, Suite 700 Cambridge, Massachusetts 02139, United States of America

[72] 1. NETHERTON, MATTHEW  
2. BRUCLE, FRANCOIS  
3. VOIGT, JOHANNES, H.  
4. WILSON, KEVIN, J.

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos.

404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan  
BS8811, Brunei Darussalam.

[31][32][33]

No. 63/186,550 Date: 30/04/2021 Country: United States of America

No. 63/325,716 Date: 31/03/2022 Country: United States of America

[86] PCT/US2022/028511

[87] WO/2022/240825

[51] C07D 403/12, C07D 495/04, A61K 31/5025

[57] The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

---

[21] BN/N/2023/0118

[22] 04/10/2023

[54] Sotorasib Formulation

[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America

[72] 1. ALVAREZ-NUNEZ, FERNANDO ANTONIO  
2. BAO, JIEMIN  
3. CHAMARTHY, SAI PRASANTH  
4. DAURIO, DOMINICK PAUL  
5. DUGGIRALA, NAGA  
6. HOUK, BRETT E.  
7. KIANG, YUAN-HON  
8. OLSOFSKY, ANGELA  
9. SAWANT, NAMITA

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 63/184,941 Date: 06/05/2021 Country: United States of America

No. 63/212,316 Date: 18/06/2021 Country: United States of America

[86] PCT/US2022/027830

[87] WO/2022/235904

[51] A61K 31/519, A61K 9/20, A61P 35/00

[57] The disclosure provides formulations comprising sotorasib (1), a diluent, a disintegrant and a lubricant.





FIG. 11

[21] BN/N/2023/0119

[22] 04/11/2023

[54] Allosteric Chromenone Inhibitors Of Phosphoinositide 3-Kinase (Pi3k) For The Treatment Of Disease

[71] PETRA PHARMA CORPORATION of 450 E 29th Street, Suite 506, New York, NY 10016, United States of America

[72] 1. ANDERSON, ERIN, DANIELLE  
2. ARONOW, SEAN, DOUGLAS  
3. BOYLES, NICHOLAS, A.  
4. CHEN, XIAOHONG  
5. DAWADI, SURENDRA  
6. HICKEY, EUGENE, R.  
7. IRVIN, THOMAS  
8. KESICKI, EDWARD, A.  
9. KNIGHT, JENNIFER, LYNN  
10. KUMAR, MANOJ  
11. LONG, KATELYN, FRANCES  
12. PICADO, ALFREDO  
13. POTOTSCHNIG, GERIT, MARIA  
14. WANG, HUA-YU  
15. WIDJAJA, TIEN  
16. WRIGHT, NATHAN, EDWARD

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos.



404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan  
BS8811, Brunei Darussalam.

[31][32][33]

No. 63/183,355 Date: 03/05/2021 Country: United States of America

No. 63/227,526 Date: 30/07/2021 Country: United States of America

No. 63/250,530 Date: 30/09/2021 Country: United States of America


No. 63/253,232 Date: 07/10/2021 Country: United States of America

[86] PCT/US2022/027304

[87] WO/2022/235574

[51] C07D 311/30, C07D 405/04, C07D 405/10, C07D 405/12, C07D 407/04, A61P 35/00

[57] The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 -kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I) or pharmaceutically acceptable salts thereof wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub>, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.



(I)

[21] BN/N/2023/0120

[22] 06/11/2023

[54] Cycloalkyl 3-Oxopiperazine Carboxamides And Cycloheteroalkyl 3-Oxopiperazine Carboxamides As Nav1.8 Inhibitors

[71] MERCK SHARP & DOHME LLC of 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, United States of America

[72] 1. ARASAPPAN, ASHOK

2. BELL, IAN, M.

3. COX, JASON, M.

4. KELLY, MICHAEL, J.
5. LAYTON, MARK ERIC
6. LIU, HONG
7. LIU, JIAN
8. SHAH, AKSHAY, A.
9. VANHEYST, MICHAEL, D.

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanca, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 63/185,637 Date: 07/06/2021 Country: United States of America


No. 63/286,691 Date: 07/12/2021 Country: United States of America

[86] PCT/US2022/027763

[87] WO/2022/235859

[51] C07D 241/08, C07D 401/12, C07D 405/12, C07D 417/12, A61K 31/496, A61P 29/00

[57] Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of Formula I may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.



[21] BN/N/2023/0121

[22] 07/11/2023

[54] Genomic Deletion In African Swine Fever Vaccine Allowing Efficient Growth In Stable Cell Lines

[71] THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE of 1400 Independence Ave. S.W. Washington, District of Columbia 20250, United States of America

[72] 1. GLADUE, DOUGLAS P.

## 2. BORCA, Manuel V.

[74] Messrs. GATEWAY LAW CORPORATION of AIP LAW, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 17/130,814 Date: 22/12/2020 Country: United States of America

[86] PCT/US2021/024124

[87] WO/2022/139861WO/2022/235859

[51] C07K 14/005, C12N 7/00, A61K 39/12, A61P 31/20

[57] Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate ("ASFV-G"). An exemplary vaccine comprises a deletion of multiple genes allowing for industrial-scale growth in stable cell lines.





FIG. 1

- [21] BN/N/2023/0102 [22] 18/09/2023
- [54] Aryl Heterocyclic Compounds As Kv1.3 Potassium Shaker Channel Blockers
- [71] D.E. SHAW RESEARCH, LLC of 120 W. 45th Street - 39th Floor, New York, New York 10036, United States of America
- [72] 1. GIORDANETTO, FABRIZIO  
2. JENSEN, MORTEN ØSTERGAARD  
3. JOGINI, VISHWANATH  
4. SNOW, ROGER JOHN
- [74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemanha, Bandar Seri Begawan BS8811, Brunei Darussalam.
- [31][32][33]  
No. 17/168,056 Date: 30/03/2021 Country: United States of America
- [86] PCT/US2022/022230
- [87] WO/2022/212296
- [51] C07D 213/75, C07D 401/12, A61P 35/00
- [57] A compound of Formula (I), (I'), (II), (II'), (III), or (IV) or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.





[71]            **ASTRAZENECA AB of 151 85 Södertälje, Sweden**

[72]            **1. SIMPSON, DAVID BRADLEY BROOK**  
**2. REN, HAIXIA**

[74]            **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

**No. PCT/CN2021/081978 Date: 22/03/2021 Country: China**

[86]            **PCT/EP2022/057305**

[87]            **WO/2022/200251**

[51]            **A61K 31/5377, A61K 35/00, A61K 9/20**

[57]            **A pharmaceutical formulation which comprises ceralasertib, dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate is described.**

---

.....

**REGISTRAR OF PATENT  
BRUNEI DARUSSALAM**

**PATENTS RULES [S 11/2013]**

**PATENT RENEWAL APPLICATION**

**Patent No.:** BN/N/2015/0093  
**Date of Grant:** 22 May, 2017  
**Annuity:** 9<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** UNIVERSITI BRUNEI DARUSSALAM  
**Title of Invention:** A Method To Enhance The Efficiency Of Dye Sensitized And Perovskite Solar Cell

---

**Patent No.:** BN/N/2015/0119  
**Date of Grant:** 06 November, 2014  
**Annuity:** 9<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** WCM OIL & GAS SDN BHD  
**Title of Invention:** Welding Isolation Chamber Habitat System

---

**Patent No.:** BN/N/2016/0005  
**Date of Grant:** 04 August, 2014  
**Annuity:** 10<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** KOURIS, PAUL, STEVEN  
**Title of Invention:** An Assembly For Generating Electricity

---

**Patent No.:** BN/N/2017/0082  
**Date of Grant:** 5 August, 2016  
**Annuity:** 8<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** CS CONSTRUCTION & GEOTECHNIC PTE LTD

**Title of Invention:** System And Method For Securing, Moving And Placing A Pile Or Heavy Elongated Object

---

**Patent No.:** BN/N/2018/0018

**Date of Grant:** 15 September, 2016

**Annuity:** 8<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ASTRAZENECA AB

**Title of Invention:** 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1-Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer

---

**Patent No.:** BN/N/2018/0104

**Date of Grant:** 16 September, 2016

**Annuity:** 7<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NIPPON STEEL & SUMITOMO METAL CORPORATION  
VALLOUREC OIL AND GAS FRANCE

**Title of Invention:** Threaded Connection

---

**Patent No.:** RE/R/2012/0061

**Date of Grant:** 29 July, 2011

**Annuity:** 13<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** HELSINN HEALTHCARE SA

**Title of Invention:** Liquid Pharmaceutical Formulations Of Palonosetron

---

**Patent No.:** RE/R/2013/0017

**Date of Grant:** 31 July, 2009

**Annuity:** 15<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** THOMSON LICENSING  
**Title of Invention:** Method For Representing Animated Menu Buttons

---

**Patent No.:** RE/R/2013/0059  
**Date of Grant:** 31 July, 2012  
**Annuity:** 12<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** PIERRE FABRE MEDICAMENT  
**Title of Invention:** Novel Antibodies Inhibiting C-Met Dimerization, And Uses Thereof

---

**Patent No.:** RE/R/2013/0062  
**Date of Grant:** 24 August, 2007  
**Annuity:** 17<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** PURDUE PHARMA L.P.  
**Title of Invention:** Tamper Resistent Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic

---

**Patent No.:** RE/R/2013/0090  
**Date of Grant:** 30 August, 2013  
**Annuity:** 11<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
**Title of Invention:** Treatment For Diabetes In Patients Inappropriate For Metformin Therapy

---

**Patent No.:** RE/R/2015/0023  
**Date of Grant:** 31 July, 2014  
**Annuity:** 10<sup>th</sup> Year



**Applicant(s) / Proprietor(s):** HALLIBURTON ENERGY SERVICES, INC.

**Title of Invention:** Treatment Fluids Comprising Relative Permeability Modifiers And Methods Of Use

---

**Patent No.:** RE/R/2015/0034

**Date of Grant:** 13 August, 2014

**Annuity:** 10<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** BIOGEN MA INC.

**Title of Invention:** Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof

---

**Patent No.:** RE/R/2015/0047

**Date of Grant:** 31 July, 2014

**Annuity:** 10<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** OIL STATES INTERNATIONAL

**Title of Invention:** Two-Element Tandem Flexible Joint

---

**Patent No.:** RE/R/2015/0070

**Date of Grant:** 12 August, 2015

**Annuity:** 9<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ALMIRALL, S.A.

**Title of Invention:** Inhalation Composition Containing Aclidinium For Treatment Of Chronic Obstructive Pulmonary Disease

---

**Patent No.:** RE/R/2017/0026

**Date of Grant:** 30 August, 2016

**Annuity:** 8<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** GLAXOSMITHKLINE LLC



**Title of Invention:** **Novel Phamaceutical Composition**

---

**Patent No.:** **RE/R/2017/0041**

**Date of Grant:** **24 August, 2016**

**Annuity:** **8<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **IMMUNOGEN, INC.**

**Title of Invention:** **Folate Receptor 1 Antibodies And Immunoconjugates And Uses Thereof**

---

**Patent No.:** **RE/R/2018/0026**

**Date of Grant:** **31 July, 2017**

**Annuity:** **7<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **KUDOS PHARMACEUTICALS LIMITED**

**Title of Invention:** **Phthalazinone Derivative**

---

**Patent No.:** **RE/R/2018/0027**

**Date of Grant:** **30 July, 2017**

**Annuity:** **7<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **AMGEN K-A, INC.**

**Title of Invention:** **Lyophilized Therapeutic Peptibody Formulations**

---

**Patent No.:** **RE/R/2018/0030**

**Date of Grant:** **15 August, 2017**

**Annuity:** **7<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **AMGEN RESEARCH (MUNICH) GMBH**

**Title of Invention:** **Means And Methods For Treating D1blcl**

---



**Patent No.:** RE/R/2019/0010  
**Date of Grant:** 22 August, 2018  
**Annuity:** 6<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** VIIV HEALTHCARE COMPANY  
**Title of Invention:** Antiviral Therapy

---

**Patent No.:** RP/R/2005/0002  
**Date of Grant:** 12 November, 1998  
**Annuity:** 20<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** JANSSEN PHARMACEUTICA N.V.  
**Title of Invention:** Aqueous Suspensions Of Submicron 9-Hydroxyrisperidone Fatty Acid Esters

---

**Patent No.:** RP/R/2005/0006  
**Date of Grant:** 01 September, 2004  
**Annuity:** 20<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** SHELL INTERNATIONALE RESEARCH  
MAATSCHAPPIJ B.V.  
**Title of Invention:** Method For Annular Sealing

---

**Patent No.:** BN/N/2014/0087  
**Date of Grant:** 11 March, 2011  
**Annuity:** 11<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** AZMI, MOIN UZZAMAN  
**Title of Invention:** Wash Basin With Foot Washing Facility

---



**Patent No.:** BN/N/2015/0081

**Date of Grant:** 19 September, 2013

**Annuity:** 11<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** SAIPEM S.A  
TOTAL SA  
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX  
VWS WESTGARTH LTD

**Title of Invention:** Underwater Water Treatment Unit And Method For Cleaning Said Unit

---

**Patent No.:** BN/N/2017/0019

**Date of Grant:** 8 September, 2015

**Annuity:** 9<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ELI LILLY AND COMPANY

**Title of Invention:** Treatment Of Androgen Deprivation Therapy Associated Symptoms

---

**Patent No.:** BN/N/2018/0023

**Date of Grant:** 30 August, 2016

**Annuity:** 8<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** PIPELIFE NEDERLAND B.V.

**Title of Invention:** High Pressure Pipe And Method For Producing Such Pipe

---

**Patent No.:** RE/R/2012/0006

**Date of Grant:** 15 September, 2011

**Annuity:** 13<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** BOEHRINGER INGELHEIM INTERNATIONAL GMBH

**Title of Invention:** Polymorphs

---

**Patent No.:** RE/R/2012/0016

**Date of Grant:** 11 September, 2007

**Annuity:** 17<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** TAKEDA PHARMACEUTICAL COMPANY LIMITED

**Title of Invention:** 2-6-(3-Amino-Piperidin-1-Yl)-3-Methyl-2, 4-Dioxo-3, 4-Dihydro-2h-Pyrimidin-1-Ylmethyl-4-Fluoro-Benzonitrile For Treating Diabetes, Cancer, Autoimmune Disorders And Hiv Infection

---

**Patent No.:** RE/R/2012/0049

**Date of Grant:** 29 August, 2006

**Annuity:** 18<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** TAKEDA PHARMACEUTICAL COMPANY LIMITED

**Title of Invention:** 1 - Heterocyclysulfonyl, 2 - Aminomethyl, 5 - (Hetero - ) Aryl Substituted 1 - H - Pyrrole Derivatives As Acid Secretion Inhibitors

---

**Patent No.:** RE/R/2013/0067

**Date of Grant:** 29 August, 2008

**Annuity:** 16<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** PURDUE PHARMA L.P.

**Title of Invention:** Substituted-Quinoxaline-Type-Piperidine Compounds And The Uses Thereof

---

**Patent No.:** RE/R/2014/0055

**Date of Grant:** 30 September, 2011

**Annuity:** 13<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NOVARTIS AG

**Title of Invention:** Combination Of Glycopyrrrolate And Beta2 Adrenoceptor Agonists

---

**Patent No.:** RE/R/2018/0033  
**Date of Grant:** 08 September, 2017  
**Annuity:** 7<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** ABBVIE INC.  
ABBVIE DEUTSCHLAND GMBH & CO KG  
**Title of Invention:** Monoclonal Antibodies And Uses Thereof

---

**Patent No.:** RP/R/2011/0041  
**Date of Grant:** 29 August, 2006  
**Annuity:** 18<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** TAKEDA PHARMACEUTICAL COMPANY LIMITED  
**Title of Invention:** 1-Heterocyclisulfonyl, 2-Aminomethyl, 5- (Hetero-) Aryl  
Substituted 1-H-Pyrrole Derivatives As Acid Secretion  
Inhibitors

---

**Patent No.:** RP/R/2011/0047  
**Date of Grant:** 01 September, 2006  
**Annuity:** 18<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** PFIZER LIMITED  
**Title of Invention:** Carboxamide Derivatives As Muscarinic Receptor  
Antagonists

---

**Patent No.:** BN/N/2015/0017  
**Date of Grant:** 26 September, 2012  
**Annuity:** 12<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** HALLIBURTON ENERGY SERVICES, INC.  
**Title of Invention:** Single Trip Multi-Zone Completion Systems And Methods



---

<b>Patent No.:</b>	<b>BN/N/2015/0021</b>
<b>Date of Grant:</b>	<b>26 September, 2012</b>
<b>Annuity:</b>	<b>12<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>HALLIBURTON ENERGY SERVICES, INC.</b>
<b>Title of Invention:</b>	<b>Tubing Conveyed Multiple Zone Integrated Intelligent Well Completion</b>

---

<b>Patent No.:</b>	<b>BN/N/2015/0027</b>
<b>Date of Grant:</b>	<b>26 September, 2012</b>
<b>Annuity:</b>	<b>12<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>HALLIBURTON ENERGY SERVICES, INC.</b>
<b>Title of Invention:</b>	<b>Completion Assembly And Methods For Use Thereof</b>

---

<b>Patent No.:</b>	<b>BN/N/2015/0030</b>
<b>Date of Grant:</b>	<b>26 September, 2012</b>
<b>Annuity:</b>	<b>12<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>HALLIBURTON ENERGY SERVICES, INC.</b>
<b>Title of Invention:</b>	<b>Single Trip Multi-Zone Completion Systems And Methods</b>

---

<b>Patent No.:</b>	<b>BN/N/2019/0055</b>
<b>Date of Grant:</b>	<b>30 October, 2017</b>
<b>Annuity:</b>	<b>7<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>SHELL INTERNATIONAL RESEARCH MAATSCHAPPIJ B.V.</b>
<b>Title of Invention:</b>	<b>Method For Sealing Cavities In Or Adjacent To A Cured Cement Sheath Surrounding A Well Casing</b>

---

**Patent No.:** BN/N/2020/0023  
**Date of Grant:** 26 September, 2018  
**Annuity:** 6<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** INCYTE CORPORATION  
**Title of Invention:** Salts Of Pyrrolotriazine Derivatives Useful As Tam Inhibitors

---

**Patent No.:** BN/N/2020/0113  
**Date of Grant:** 20 June, 2019  
**Annuity:** 5<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** MERCK SHARP & DOHME LLC  
**Title of Invention:** PCSK9 Antagonist Compounds

---

**Patent No.:** RE/R/2012/0022  
**Date of Grant:** 13 September, 2006  
**Annuity:** 18<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** TAKEDA PHARMACEUTICAL COMPANY LIMITED  
**Title of Invention:** Dipeptidyl Peptidase Inhibitors For Treating Diabetes

---

**Patent No.:** RE/R/2013/0092  
**Date of Grant:** 13 September, 2006  
**Annuity:** 18<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** TAKEDA PHARMACEUTICAL COMPANY LIMITED  
**Title of Invention:** Administration Of Dipeptidyl Peptidase Inhibitors

---

**Patent No.:** RE/R/2014/0011



**Date of Grant:** 28 June, 2013  
**Annuity:** 11<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** SINGAPORE AIRLINES LIMITED  
**Title of Invention:** Aircraft Seating And Seating Arrangements

---

**Patent No.:** RE/R/2016/0049  
**Date of Grant:** 20 October, 2016  
**Annuity:** 8<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** JANSSEN SCIENCES IRELAND UC  
**Title of Invention:** Aqueous Suspensions Of TMC278

---

**Patent No.:** RE/R/2018/0035  
**Date of Grant:** 18 October, 2017  
**Annuity:** 7<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** ASTRAZENECA AB  
**Title of Invention:** N-Acylsulfonamide Apoptosis Promoters

---

**Patent No.:** RP/R/2009/0021  
**Date of Grant:** 08 October, 2008  
**Annuity:** 16<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** SHELL INTERNATIONAL RESEARCH  
MAATSCHAPPIJ B.V.  
**Title of Invention:** Borehole Imaging

---

**Patent No.:** RP/R/2009/0037  
**Date of Grant:** 07 October, 2009

**Annuity:** 15<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** SHELL INTERNATIONALE RESEARCH  
MAATSCHAPPIJ B. V

**Title of Invention:** Method For Optimising The Production Of A Cluster Of Wells

---

**Patent No.:** BN/N/2014/0025

**Date of Grant:** 16 November, 2012

**Annuity:** 12<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NIPPON STEEL & SUMITOMO METAL  
CORPORATION  
VALLOUREC OIL AND GAS FRANCE

**Title of Invention:** Tubular Threaded Joint Having Improved High Torque Performance

---

**Patent No.:** BN/N/2014/0039

**Date of Grant:** 18 October, 2012

**Annuity:** 12<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** TOTAL SA

**Title of Invention:** A Floating Offshore Facility And A Method For Drilling A Well

---

**Patent No.:** BN/N/2016/0017

**Date of Grant:** 09 February, 2016

**Annuity:** 9<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** PIXELA CORPORATION  
UNIVERSITI BRUNEI DARUSSALAM

**Title of Invention:** Thermo-Shielding Window Coating Composition And Method

---

**Patent No.:** BN/N/2016/0028

**Date of Grant:** 10 October, 2014  
**Annuity:** 10<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** BERLIN-CHEMIE AG  
**Title of Invention:** Conjugated Antibodies Against Ly75 For The Treatment Of Cancer

---

**Patent No.:** BN/N/2016/0033  
**Date of Grant:** 28 October, 2014  
**Annuity:** 10<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** ELI LILLY AND COMPANY  
**Title of Invention:** Glucopyranosyl-Substituted Indole-Urea Derivatives And Their Use As Sglt Inhibitors

---

**Patent No.:** BN/N/2017/0035  
**Date of Grant:** 09 November, 2015  
**Annuity:** 9<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** MEDIMMUNE LIMITED  
**Title of Invention:** Binding Molecules Specific For Cd73 And Uses Thereof

---

**Patent No.:** BN/N/2017/0044  
**Date of Grant:** 30 November, 2015  
**Annuity:** 9<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** ASTRAZENECA AB  
**Title of Invention:** 1-[2-(Aminomethyl)Benzyl]-2-Thioxo-1,2,3,5-Tetrahydro-4h-Pyrrolo[3,2-D]Pyrimidin-4-Ones As Inhibitors Of Myeloperoxidase

---

**Patent No.:** BN/N/2018/0016



**Date of Grant:** 21 October, 2016

**Annuity:** 8<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NANYANG TECHNOLOGICAL UNIVERSITY  
PROGEN PTE LTD

**Title of Invention:** Passive Chilled Panel

---

**Patent No.:** BN/N/2018/0036

**Date of Grant:** 16 December, 2016

**Annuity:** 8<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NIPPON STEEL & SUMITOMO METAL  
CORPORATION  
VALLOUREC OIL AND GAS FRANCE

**Title of Invention:** Threaded Connection For Pipe Or Tube And Method Of  
Producing The Threaded Connection For Pipe Or Tube

---

**Patent No.:** BN/N/2019/0048

**Date of Grant:** 13 October, 2017

**Annuity:** 7<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** MEDIMMUNE LIMITED

**Title of Invention:** Pyrrolobenzodiazepine Conjugates

---

**Patent No.:** BN/N/2019/0052

**Date of Grant:** 10 October, 2017

**Annuity:** 7<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ARRAY BIOPHARMA INC.

**Title of Invention:** Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret  
Kinase Inhibitors

---

**Patent No.:** BN/N/2020/0032

**Date of Grant:** 17 October, 2018

**Annuity:** 6<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** INCYTE CORPORATION

**Title of Invention:** Condensed Imidazole Derivatives Substituted By Tertiary Hydroxy Groups As Pi3k-Gamma Inhibitors

---

**Patent No.:** BN/N/2020/0033

**Date of Grant:** 17 October, 2018

**Annuity:** 6<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** HYDRA SYSTEMS AS

**Title of Invention:** A System And Method Of Cleaning An Annular Area In A Well

---

**Patent No.:** BN/N/2020/0038

**Date of Grant:** 15 November, 2018

**Annuity:** 6<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** SHELL INTERNATIONAL RESEARCH  
MAATSCHAPPIJ B.V.

**Title of Invention:** Method Of Restraining Migration Of Formation Solids In A Wellbore

---

**Patent No.:** BN/N/2020/0041

**Date of Grant:** 19 November, 2018

**Annuity:** 6<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** WEATHERFORD U.K. LIMITED

**Title of Invention:** Method And Apparatus For Washing An Annulus

---

**Patent No.:** BN/N/2020/0047

**Date of Grant:** 04 December, 2018

**Annuity:** 6<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** MERCK SHARP & DOHME LLC

**Title of Invention:** Compositions Comprising Streptococcus Pneumoniae Polysaccharide-Protein Conjugates And Methods Of Use Thereof

---

**Patent No.:** BN/N/2020/0069

**Date of Grant:** 19 July, 2018

**Annuity:** 5<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** C&M OILFIELD RENTALS, LLC

**Title of Invention:** Improved Elevated Structure-Mounted Lighting System

---

**Patent No.:** BN/N/2020/0100

**Date of Grant:** 16 April, 2019

**Annuity:** 5<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** SHELL INTERNATIONALE RESEARCH  
MAATSCHAPPIJ B.V.

**Title of Invention:** Synthetic Modeling With Noise Simulation

---

**Patent No.:** BN/N/2020/0101

**Date of Grant:** 16 April, 2019

**Annuity:** 5<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** SHELL RESEARCH MAATSCHAPPIJ B.V.

**Title of Invention:** Synthetic Modeling

---

**Patent No.:** BN/R/2020/0006

**Date of Grant:** 24 November, 2010

**Annuity:** 14<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** MEDIMMUNE LIMITED  
**Title of Invention:** Targeted Binding Agents Against B7-H1

---

**Patent No.:** BN/R/2021/0004  
**Date of Grant:** 09 October, 2020  
**Annuity:** 5<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** DOLBY INTERNATIONAL AB  
**Title of Invention:** Cross Product Enhanced Harmonic Transportation

---

**Patent No.:** RE/R/2012/0029  
**Date of Grant:** 30 November, 2009  
**Annuity:** 15<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** PEAK WELL SYSTEMS PTY LTD  
**Title of Invention:** A Retrievable Downhole Tool And Running Tool

---

**Patent No.:** RE/R/2012/0056  
**Date of Grant:** 15 November, 2011  
**Annuity:** 13<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** HIGH SEALED AND COUPLED "HSC" FZCO  
**Title of Invention:** An Improved Seal Between Pipes

---

**Patent No.:** RE/R/2012/0062  
**Date of Grant:** 23 October, 2006  
**Annuity:** 18<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** ABBOTT LABORATORIES



**Title of Invention:** Infant Formulas Containing Docosahexaenoic Acid And Lutein

---

**Patent No.:** RE/R/2013/0086

**Date of Grant:** 30 November, 2011

**Annuity:** 13<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** JANSSEN PHARMACEUTICA N.V

**Title of Invention:** Processes For The Preparation Of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile

---

**Patent No.:** RE/R/2014/0017

**Date of Grant:** 15 November, 2013

**Annuity:** 11<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** SUMITOMO METAL INDUSTRIES LTD.  
VALLOUREC MANNESMANN OIL & GAS FRANCE

**Title of Invention:** Threaded Joint For Steel Pipes

---

**Patent No.:** RE/R/2014/0067

**Date of Grant:** 20 November, 2013

**Annuity:** 11<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ASTRAZENECA AB

**Title of Invention:** Pyrimidine Sulphonamide Derivatives As Chemokine Receptor Modulators

---

**Patent No.:** RE/R/2015/0051

**Date of Grant:** 19 November, 2014

**Annuity:** 10<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** WYETH LLC





**Title of Invention:** **Processes For The Convergent Synthesis Of Calicheamicin Derivatives**

---

**Patent No.:** **RE/R/2015/0055**

**Date of Grant:** **10 December, 2014**

**Annuity:** **10<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **PFIZER INC.**

**Title of Invention:** **Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives**

---

**Patent No.:** **RE/R/2016/0004**

**Date of Grant:** **15 October, 2015**

**Annuity:** **9<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **PFIZER INC**

**Title of Invention:** **Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives**

---

**Patent No.:** **RE/R/2016/0031**

**Date of Grant:** **16 December, 2015**

**Annuity:** **9<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **MERCK SHARP & DOHME LLC**

**Title of Invention:** **Iminothiadiazine Dioxide Compounds As Bace Inhibitors, Compositions, And Their Use**

---

**Patent No.:** **RE/R/2016/0046**

**Date of Grant:** **25 November, 2015**

**Annuity:** **9<sup>th</sup> Year**

**Applicant(s) / Proprietor(s):** **ACCELERON PHARMA INC.**

**Title of Invention:** **ActRII Receptor Polypeptides**



---

<b>Patent No.:</b>	<b>RE/R/2017/0048</b>
<b>Date of Grant:</b>	<b>02 November, 2016</b>
<b>Annuity:</b>	<b>8<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>MSD K.K.</b>
<b>Title of Invention:</b>	<b>Dihydropyrazolopyrimidinone Derivative</b>

---

<b>Patent No.:</b>	<b>RE/R/2017/0050</b>
<b>Date of Grant:</b>	<b>14 October, 2016</b>
<b>Annuity:</b>	<b>8<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>GENENTECH, INC.</b>
<b>Title of Invention:</b>	<b>Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof</b>

---

<b>Patent No.:</b>	<b>RE/R/2017/0056</b>
<b>Date of Grant:</b>	<b>31 October, 2016</b>
<b>Annuity:</b>	<b>8<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>IMMUNOGEN, INC.</b>
<b>Title of Invention:</b>	<b>Cross-Linkers And Their Uses</b>

---

<b>Patent No.:</b>	<b>RE/R/2017/0058</b>
<b>Date of Grant:</b>	<b>15 November, 2016</b>
<b>Annuity:</b>	<b>8<sup>th</sup> Year</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>PETROLIAM NASIONAL BERHAD (PETRONAS)</b>
<b>Title of Invention:</b>	<b>Water Curable Resin Formulations</b>

---



**Patent No.:** RE/R/2018/0007  
**Date of Grant:** 02 November, 2017  
**Annuity:** 7<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** NIPPON SHINYAKU CO., LTD.  
**Title of Invention:** Crystals

---

**Patent No.:** RE/R/2018/0034  
**Date of Grant:** 13 October, 2017  
**Annuity:** 7<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** TENZA ENGINEERING SDN. BHD.  
**Title of Invention:** Apparatus And Method For Manufacturing A Spiral Tank

---

**Patent No.:** BN/N/2019/0081  
**Date of Grant:** 19 December, 2017  
**Annuity:** 7<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** ASTRAZENECA AB  
**Title of Invention:** Amino-Triazolopyridine Compounds And Their Use In Treating Cancer

---

**Patent No.:** BN/N/2019/0120  
**Date of Grant:** 11 April, 2018  
**Annuity:** 5<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** NIPPON STEEL CORPORATION  
VALLOUREC OIL AND GAS FRANCE  
**Title of Invention:** Threaded Connection For Steel Pipes

---

**Patent No.:** BN/N/2019/0120

**Date of Grant:** 11 April, 2018

**Annuity:** 6<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NIPPON STEEL CORPORATION  
VALLOUREC OIL AND GAS FRANCE

**Title of Invention:** Threaded Connection For Steel Pipes

---

**Patent No.:** RE/R/2013/0020

**Date of Grant:** 22 December, 2004

**Annuity:** 20<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ASTRAZENECA AB

**Title of Invention:** Maleate Salts Of A Quinazoline Derivative Useful As An Antiangiogenic Agent

---

**Patent No.:** RE/R/2015/0062

**Date of Grant:** 26 November, 2014

**Annuity:** 10<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NEWRON PHARMACEUTICALS S.P.A.

**Title of Invention:** Process For The Production Of 2- [4 - ( 3- And 2- Fluorobenzyl)oxy) Benzylamin] Propan Amides

---

**Patent No.:** RE/R/2015/0066

**Date of Grant:** 31 December, 2014

**Annuity:** 10<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** ARDEA BIOSCIENCES, INC.

**Title of Invention:** Thioacetate Compounds, Compositions And Methods Of Use

---

**Patent No.:** RE/R/2015/0069

**Date of Grant:** 23 December, 2014

**Annuity:** 10<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** GILEAD BIOLOGICS, INC.  
**Title of Invention:** Antibodies That Bind To Lysyl Oxidase-Like 2(Loxl2) And Methods Of Use Therefor

---

**Patent No.:** RE/R/2017/0008  
**Date of Grant:** 07 December, 2016  
**Annuity:** 8<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** GILEAD BIOLOGICS, INC.  
**Title of Invention:** Method Of Preparing An Inhibitor Of Cytochrome P450 Monooxygenase, And Intermediates Involved

---

**Patent No.:** RE/R/2019/0014  
**Date of Grant:** 23 September, 2019  
**Annuity:** 5<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** BESPOKE BIOSCIENCE, LLC  
**Title of Invention:** Compositions And Method Of Aloe Polysaccharides

---

**Patent No.:** RP/R/2009/0039  
**Date of Grant:** 17 December, 2008  
**Annuity:** 16<sup>th</sup> Year  
**Applicant(s) / Proprietor(s):** SHELL INTERNATIONAL RESEARCH  
MAATSCHAPPIJ B.V.  
**Title of Invention:** Method For Expanding A Steel Tubing And Well With Such As Tubing

---

**Patent No.:** RP/R/2010/0012  
**Date of Grant:** 19 November, 2008



**Annuity:** 16<sup>th</sup> Year

**Applicant(s) / Proprietor(s):** NOVARTIS AG

**Title of Invention:** Inhibitors Of Tyrosine Kinases

---

.....



**REGISTRAR OF PATENT  
BRUNEI DARUSSALAM**

**PATENTS RULES [S 11/2013]**

**PATENT GRANTED UNDER SECTION 30**

<b>Application No.:</b>	<b>BN/N/2019/0110</b>
<b>Date of Grant:</b>	<b>30 September, 2020</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>CAE INC.</b>
<b>Title of Invention:</b>	<b>Continuous Monitoring Of A Model In An Interactive Computer Simulation Station</b>

---

<b>Application No.:</b>	<b>BN/N/2020/0114</b>
<b>Date of Grant:</b>	<b>21 June, 2023</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>ELI LILLY AND COMPANY</b>
<b>Title of Invention:</b>	<b>GIP/GLP1 Agonist Compositions</b>

---

<b>Application No.:</b>	<b>BN/N/2021/0020</b>
<b>Date of Grant:</b>	<b>05 September, 2023</b>
<b>Applicant(s) / Proprietor(s):</b>	<b>ELI LILLY AND COMPANY</b>
<b>Title of Invention:</b>	<b>2,6-Diamino Pyridine Compounds</b>

---

.....

**REGISTRAR OF PATENT**  
**BRUNEI DARUSSALAM**

**PATENTS RULES [S 11/2013]**

**RECORDAL OF CHANGE OF NAME & ADDRESS**

(The name in *italic* is the previous proprietor's name & address)

**Application No.:** BN/N/2022/0130

**Applicant(s) / Proprietor(s):** APEX WATER SOLUTIONS AND SERVICES of Building No. 19, Street: 854, Zone: 40 Doha, Qatar  
*APEX WATER SOLUTION LLC of Building No. 19, Street: 854, Zone: 40 Doha, Qatar*

**Title of Invention:** Methods For Treating Porous Membranes

**Agent and/ or Address for Service :**

Messrs. DREW & NAPIER LLC of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

---

**Application No.:** BN/N/2021/0036

**Applicant(s) / Proprietor(s):** BE INTERNATIONAL MARKETING SDN BHD of C-20-G, Jalil Link 2 No. 5, Jalan Jalil Perkasa 1, Bukit Jalil, 57000 Kuala Lumpur, Malaysia  
*BE INTERNATIONAL MARKETING SDN BHD of C-20-G, Jalil Link 2 No. 5, Jalan Perkasa 1, Bukit Jalil, 57000 Kuala Lumpur, Malaysia*

**Title of Invention:** Compression Garment Incorporated With Far-Infrared (Fir) Emitting Particles

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam

---

**Application No.:** BN/N/2022/0091

**Applicant(s) / Proprietor(s):** AMGEN INC. of One Amgen Center Drive Thousand Oaks,





California 91320-1799 United States of America

**Inventor:** TALLY, CLEA  
TALLEY, CLEA

**Title of Invention:** Formulations Of Human Anti-Tslp Antibodies And  
Methods Of Treating Inflammatory Disease

**Agent and/ or Address for Service:**

Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of PO Box 368 404A-410A, 4thFloor AIP  
Law Wisma Jaya Jalan Pemanha Bandar Seri Begawan BS8811 Brunei Darussalam

---

**Application No.:** BN/N/2023/0034

**Applicant(s) / Proprietor(s):** APEX WATER SOLUTION LLC of Building No. 19,  
Street: 854, zone: 40 Doha  
APEX WATER SOLUTIONS AND SERVICES of Building  
No. 19, Street: 854, zone: 40 Doha

**Title of Invention:** Processes For Forming Functionalized  
Membranes

**Agent and/ or Address for Service :**

Messrs. DREW & NAPIER LLC of AIP Law Unit Nos. 404A-410A 4th Floor, Wisma Jaya  
Jalan Pemanha Bandar Seri Begawan BS8811 Brunei Darussalam

---

**Application No.:** RE/R/2017/0005

**Applicant(s) / Proprietor(s):** ESTEVE PHARMACEUTICALS, S.A. of Passeig de la  
Zona Franca, 109, 4a Planta 0808 Barcelona, Spain  
LABORATORIES DEL DR. ESTEVT S.A. of Avenida Mare  
De D'eu, De Montserrat 221 Barcelona E.

**Title of Invention:** Heat-Not-Burn Cigarette Having Cavity Container Section

**Agent and/ or Address for Service :**

Messrs. MIRANDAH ASIA (MALAYSIA) SDN BHD of AIP Law, Unit Nos. 405A-410A 4th  
Floor, Wisma Jaya Jalan Pemanha Bandar Seri Begawan BS8811 Brunei Darussalam

---



**REGISTRAR OF PATENT**

**BRUNEI DARUSSALAM**

**PATENTS RULES [S 11/2013]**

**RECORDAL OF CHANGE OF AGENT**

(The name in *italic* is the previous proprietor's name & address)

**Application No.:** BN/N/2021/0063

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17,  
Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan  
Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri  
Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2021/0064

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17,  
Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan  
Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri  
Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2021/0065

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17,  
Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2021/0066

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2022/0013

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2022/0014

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, Shandong 264006, China



**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2022/0015

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2022/0017

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, Shandong 264006, China

**Title of Invention:** Device And Method For Oxidizing Organic Substance

**Agent and/ or Address for Service :**

Messrs. PINTAS IP GROUP SDN BHD of No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Brunei Darussalam  
*Messrs. MIA MANAGEMENT SERVICES of P.O. Box 18, Anggerek Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam*

---

**Application No.:** BN/N/2022/0037

**Applicant(s) / Proprietor(s):** RECOVE GROUP SDN. BHD. of TGB-09, Block B, PUSTEK 2, UKM-MTDC Technology Centre, University



Kebangsaan Malaysia, 43600 Bangi, Selangor, Malaysia

**Title of Invention:** A Device For Measuring Jaundice Levels

**Agent and/ or Address for Service :**

Messrs. MIA MANAGEMENT SERVICES of Anggerek Desa Complex, Bandar Seri Begawan  
BB3780 Brunei  
*Messrs. PINTAS IP GROUP SDN BHD of No. 4, Spg 538-37-3, Kg Sg Akar, JIn Kebangsaan  
Lama, BC4115 Brunei*

---

**Application No.:** BN/N/2022/0044

**Applicant(s) / Proprietor(s):** THE UNITED STATES OF AMERICA, AS  
REPRESENTED BY THE SECRETARY OF  
ARGICULTURE of 1400 Independence Ave, S. W.,  
Washington, District of Columbia 20250 (US).

**Title of Invention:** Development Of A Novel Live Attenuated African Swine  
Fever Vaccine Based In The Deletion Of Gene 1177I

**Agent and/ or Address for Service :**

Messrs. MIA MANAGEMENT SERVICES of Anggerek Desa Complex, Bandar Seri Begawan  
BB3780 Brunei  
*Messrs. PINTAS IP GROUP SDN BHD of No. 4, Spg 538-37-3, Kg Sg Akar, JIn Kebangsaan  
Lama, BC4115 Brunei*

---

**Application No.:** BN/N/2022/0059

**Applicant(s) / Proprietor(s):** TANGOLD INC. of 9407-3 20th Avenue NW Edmonton,  
Alberta T6N 1E5, Canada

**Title of Invention:** Fabrication Of Carbon Fibers With High Mechanical  
Properties

**Agent and/ or Address for Service :**

Messrs. MIA MANAGEMENT SERVICES of Anggerek Desa Complex, Bandar Seri Begawan  
BB3780 Brunei  
*Messrs. PINTAS IP GROUP SDN BHD of No. 4, Spg 538-37-3, Kg Sg Akar, JIn Kebangsaan  
Lama, BC4115 Brunei*

---



**Application No.:** BN/N/2022/0070

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No.17, Tianshan Rd, YEDA, Yantai, Shandong 264006 China  
WANHUA CHEMICAL (NINGBO) CO., LTD. of 39 Huandao Road (North), Wanhua Industrial Park, Daxie Development Zone, Ningbo, Zhejiang 315812, China

**Title of Invention:** Catalytic Oxidation Catalyst, Preparation Method Therefor, And Method For Deep Treatment Of Organic Matters In Mdi Saline

**Agent and/ or Address for Service :**

Messrs. MIA MANAGEMENT SERVICES of Anggerek Desa Complex, Bandar Seri Begawan BB3780 Brunei  
*Messrs. PINTAS IP GROUP SDN BHD of No. 4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115 Brunei*

---

**Application No.:** BN/N/2022/0143

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No.17, Tianshan Rd, YEDA, Yantai, Shandong 264006 China  
WANHUA CHEMICAL (NINGBO) CO., LTD. of 39 Huandao Road (North), Wanhua Industrial Park, Daxie Development Zone, Ningbo, Zhejiang 315812, China

**Title of Invention:** Method For Preparing Mdi And Method For Preparing Phosgene

**Agent and/ or Address for Service :**

Messrs. MIA MANAGEMENT SERVICES of Anggerek Desa Complex, Bandar Seri Begawan BB3780 Brunei  
*Messrs. PINTAS IP GROUP SDN BHD of No. 4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115 Brunei*

---

**Application No.:** BN/N/2023/0003

**Applicant(s) / Proprietor(s):** WANHUA CHEMICAL GROUP CO., LTD. of No.17, Tianshan Rd, YEDA, Yantai, Shandong 264006 China

**Messrs. MIA MANAGEMENT SERVICES of Anggerek Desa Complex, Bandar Seri Begawan  
BB3780 Brunei**  
*Messrs. PINTAS IP GROUP SDN BHD of No. 4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan  
Lama, BC4115 Brunei*